Gavasso S - Search Results

1

Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease.

Gavasso S, Nygård O, Pedersen ER, Aarseth JH, Bleie O, Myhr KM, Vedeler CA. Gavasso S, et al. Atherosclerosis. 2005 Jun;180(2):277-82. doi: 10.1016/j.atherosclerosis.2004.12.011. Epub 2005 Jan 25. Atherosclerosis. 2005. PMID: 15910853

2

Early response evaluation by single cell signaling profiling in acute myeloid leukemia.

Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Baliakas P, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT. Tislevoll BS, et al. Among authors: gavasso s. Nat Commun. 2023 Jan 7;14(1):115. doi: 10.1038/s41467-022-35624-4. Nat Commun. 2023. PMID: 36611026 Free PMC article.

3

Multiplexed phosphoprotein analysis in immune cells.

Gavasso S, Myhr KM, Vedeler C. Gavasso S, et al. Acta Neurol Scand Suppl. 2006;183:58-60. doi: 10.1111/j.1600-0404.2006.00618.x. Acta Neurol Scand Suppl. 2006. PMID: 16637932 Review.

4

Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.

Gavasso S, Gjertsen B, Anderssen E, Myhr K, Vedeler C. Gavasso S, et al. Mult Scler. 2012 Aug;18(8):1116-24. doi: 10.1177/1352458511434066. Epub 2012 Jan 27. Mult Scler. 2012. PMID: 22287540

5

Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.

Gavasso S, Torkildsen Ø, Marøy TH, Ulvestad E, Myhr KM, Vedeler CA. Gavasso S, et al. Acta Neurol Scand Suppl. 2012;(195):84-9. doi: 10.1111/ane.12026. Acta Neurol Scand Suppl. 2012. PMID: 23278662

6

Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.

Gavasso S, Mosleth EF, Marøy T, Jørgensen K, Nakkestad HL, Gjertsen BT, Myhr KM, Vedeler C. Gavasso S, et al. PLoS One. 2014 Feb 19;9(2):e88632. doi: 10.1371/journal.pone.0088632. eCollection 2014. PLoS One. 2014. PMID: 24586361 Free PMC article.

7

Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories.

Bader LI, Solberg SM, Kaada SH, Bolstad N, Warren DJ, Gavasso S, Gjesdal CG, Vedeler CA. Bader LI, et al. Among authors: gavasso s. Scand J Immunol. 2017 Sep;86(3):165-170. doi: 10.1111/sji.12572. Scand J Immunol. 2017. PMID: 28561325 Free article.

8

Optimization of Receptor Occupancy Assays in Mass Cytometry: Standardization Across Channels with QSC Beads.

Bringeland GH, Bader L, Blaser N, Budzinski L, Schulz AR, Mei HE, Myhr KM, Vedeler CA, Gavasso S. Bringeland GH, et al. Among authors: gavasso s. Cytometry A. 2019 Mar;95(3):314-322. doi: 10.1002/cyto.a.23723. Epub 2019 Jan 27. Cytometry A. 2019. PMID: 30688025 Free PMC article.

9

Candidate Markers for Stratification and Classification in Rheumatoid Arthritis.

Bader L, Gullaksen SE, Blaser N, Brun M, Bringeland GH, Sulen A, Gjesdal CG, Vedeler C, Gavasso S. Bader L, et al. Among authors: gavasso s. Front Immunol. 2019 Jul 5;10:1488. doi: 10.3389/fimmu.2019.01488. eCollection 2019. Front Immunol. 2019. PMID: 31338093 Free PMC article.

10

Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.

Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S. Bringeland GH, et al. Among authors: gavasso s. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 4;7(3):e678. doi: 10.1212/NXI.0000000000000678. Print 2020 May 4. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32019768 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters